Equity Profile

LGND

Ligand Pharmaceuticals Incorporated

Health CarePharmaceuticals$5.8B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Ligand Pharmaceuticals Incorporated (LGND) is a healthcare company focused on developing and commercializing innovative therapies. With a market cap of $6 billion, it plays a significant role in the pharmaceuticals industry, particularly in drug development and licensing.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales, which is crucial for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LGND Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+287.89%

Avg Stock Reaction

+1.84%

Last Quarter Recap

In Q1-2026, Ligand reported an EPS of $1.63, significantly beating estimates by 66.84%. However, the stock fell 9.55% the following day, indicating mixed investor sentiment despite the strong earnings.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are anticipating another strong performance from Ligand, given its history of beating EPS estimates. However, the lack of revenue guidance and mixed reactions to previous earnings may create uncertainty.

Bull Case

If Ligand continues its trend of strong earnings surprises, it could see significant stock appreciation as investors regain confidence.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Ligand's history of strong EPS surprises, this number will be crucial for investor sentiment and stock performance.

Will there be any guidance on revenue growth?

Investors are looking for clarity on future revenue, which can significantly impact the stock's direction.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Ligand's ability to maintain high EPS growth, given its recent performance and historical trends.

Supporting Evidence

Ligand has consistently beaten EPS estimates, suggesting a strong operational performance.

The options market is pricing in a larger move than historical averages, indicating potential for a significant reaction.

Insider buying activity may suggest confidence in the company's future performance.

Key Risk

If EPS comes in below $1.50, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Ligand can maintain its strong earnings trajectory amidst market uncertainties.

Bull Confirmed If

An EPS of $2.00 or higher would confirm the bull case, indicating continued strong performance.

Bear Confirmed If

An EPS below $1.50 would support the bear case, suggesting potential issues with profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±15.86%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±15.9% while LGND has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

47.7%

Calls (100)P/C Ratio: 0.15Puts (300)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ligand beats expectations, history suggests a potential stock increase of around +1.84%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns suggesting a drop of around -9.55% following previous misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or partnerships.
2Details on cost management and operational efficiency.
3Insights into market conditions affecting sales.
4Any commentary on competitive landscape and market share.
5Guidance on future revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales, which is crucial for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LGND Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+287.89%

Avg Stock Reaction

+1.84%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Ligand continues its trend of strong earnings surprises, it could see significant stock appreciation as investors regain confidence.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Ligand's history of strong EPS surprises, this number will be crucial for investor sentiment and stock performance.

Will there be any guidance on revenue growth?

Investors are looking for clarity on future revenue, which can significantly impact the stock's direction.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Ligand's ability to maintain high EPS growth, given its recent performance and historical trends.

Supporting Evidence

Ligand has consistently beaten EPS estimates, suggesting a strong operational performance.

The options market is pricing in a larger move than historical averages, indicating potential for a significant reaction.

Insider buying activity may suggest confidence in the company's future performance.

Key Risk

If EPS comes in below $1.50, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Ligand can maintain its strong earnings trajectory amidst market uncertainties.

Bull Confirmed If

An EPS of $2.00 or higher would confirm the bull case, indicating continued strong performance.

Bear Confirmed If

An EPS below $1.50 would support the bear case, suggesting potential issues with profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±15.86%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±15.9% while LGND has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

47.7%

Calls (100)P/C Ratio: 0.15Puts (300)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ligand beats expectations, history suggests a potential stock increase of around +1.84%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns suggesting a drop of around -9.55% following previous misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or partnerships.
2Details on cost management and operational efficiency.
3Insights into market conditions affecting sales.
4Any commentary on competitive landscape and market share.
5Guidance on future revenue expectations.